Start Date:5/22/2024
Start Time:8:30 AM EDT
Duration:210 minutes
Abstract:
Please join members of the Scholar Rock leadership team & two key opinion leaders for Scholar Rock’s 2024 Investor Day.
If you're already registered for the Scholar Rock Investor Day webcast, click below:
ALREADY REGISTERED?
Speakers
Jay Backstrom, M.D., MPH President & CEO Scholar Rock Dr. Jay Backstrom joined Scholar Rock in October 2022 as President & CEO. He is an industry veteran with over 30 years of experience in clinical research and development. Prior to Scholar Rock, he served as Executive Vice President, Research and Development at Acceleron Pharma, from December 2019 through its acquisition by Merck in 2021. Previously, he served as the Chief Medical Officer and Head of Global Regulatory Affairs for Celgene Corporation and spent more than a decade at the company during a time of significant pipeline expansion and revenue growth. Prior to Celgene, Jay served as the Vice President, Global Medical Affairs and Safety at Pharmion and held industry roles at Quintiles, Hoechst Marion Roussel and Marion Merrell Dow. Prior to joining industry, he served as staff physician and medical director of the Samuel U. Rodgers Community Health Center in Kansas City, Missouri. Jay holds an M.D. from Temple University School of Medicine, received post-graduate training in Internal Medicine at Temple University Hospital, and holds an MPH from St. Louis University School of Public Health.
Jing Marantz, M.D., Ph.D. Chief Medical Officer Scholar Rock Jing L. Marantz joined Scholar Rock November 2022 as Chief Medical Officer, overseeing development and medical affairs. She has over 20 years of experience in the biopharmaceutical industry spanning R&D, business development, and commercial strategy in multiple specialties and rare diseases. Jing currently serves on the board of Arcturus Therapeutics (NASDAQ: ARCT). She was recently EVP and Chief Business Officer of Krystal Biotech, after serving on its board for a year. Prior to Krystal, Jing was Senior Vice President of Medical Affairs at Acceleron Pharma until its acquisition by Merck & Co., Inc. Jing has held leadership positions at Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals across development, medical affairs, and business development. She was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. She received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.
Tracey Sacco Chief Commercial Officer Scholar Rock Tracey Sacco has served as Chief Commercial Officer of Scholar Rock since February 2023. She is responsible for all commercial functions, including sales, marketing, market access, and commercial operations. Tracey has nearly two decades of biopharmaceutical industry experience, with much of her career focused on rare disease programs from early-stage development through launch. Prior to joining Scholar Rock, Ms. Sacco worked at The Nemetz Group, where she served as a strategic partner to biopharmaceutical companies on commercialization and corporate strategy. Previously, she held positions of increasing responsibility at Acceleron Pharma, most recently serving as Senior Vice President, Global Strategic Marketing. Prior to Acceleron, Ms. Sacco held roles in commercial strategy and business development at Sanofi (formerly Genzyme), Oscient Pharmaceuticals, and Pfizer. Ms. Sacco holds an MBA from NYU Stern School of Business and a B.A. in Economics and Sociology from Boston College. She is a member of the Life Science Cares Board of Advisors.
Mo Qatanani, Ph.D. Chief Scientific Officer Scholar Rock Mo Qatanani joined Scholar Rock in 2021 and has served as Chief Scientific Officer since 2024. He is responsible for all research functions, including discovery biology, protein sciences & antibody engineering, safety and translational sciences. Mo brings more than 15 years of discovery and translational research experience in developing and advancing multiple therapeutic modalities across many disease areas in the biotech and pharmaceutical industry. Prior to Scholar Rock, Mo was a founding employee, vice president, and Head of Research at Dyne Therapeutics, where he built the research organization from the ground up to launch and advance to the clinic multiple therapeutic programs for rare neuromuscular diseases. Prior to Dyne, Mo held research positions of increasing responsibility at Alexion Pharmaceuticals, Synageva BioPharma, and Merck. Mo holds a Ph.D. in molecular and human genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.
Ania Jastreboff, M.D., Ph.D. KOL Dr. Jastreboff is an Associate Professor in Medicine and Pediatrics at Yale School of Medicine. She serves as the director of the Yale Obesity Research Center (Y-Weight) and the co-director of the Yale Center for Weight Management. She is trained in both adult endocrinology and pediatric endocrinology, is an obesity medicine physician-scientist, and an international leader in research and clinical application of anti-obesity pharmacotherapeutics. Her work has included working to develop Obesity Clinical Practice Guidelines (AACE/ACE 2016), serving on the Board of Directors for the American Board of Obesity Medicine, educating the next generation of Obesity Medicine physicians by teaching at national and international obesity treatment courses, and conducting cutting-edge clinical-translational obesity research. Her research includes large, multi-center clinical outcomes trials using novel anti-obesity pharmacotherapeutics and studies examining the neurobiology underlying obesity and mechanisms of anti-obesity medications (supported by the NIH/NIDDK). Recently, she has served as lead author for trials investigating potential novel nutrient-stimulated hormone-based therapies for obesity including dual hormone receptor agonist tirzepatide (NEJM) a novel GIP/GLP-1 receptor agonist (Jastreboff, et al., NEJM, 2022) and triple hormone receptor agonist retatrutide (NEJM) a novel GIP/GLP-1/Glucagon receptor agonist (Jastreboff, et al., NEJM, 2023).
Diana Castro, M.D. KOL Dr. Castro, a board-certified neurologist, and neuromuscular physician is a pioneer in the research and management of patients with Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, and Acquired Neuropathies, like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Since completing training in pediatric neuromuscular medicine, Dr. Castro has conducted multiple clinical research trials in SMA, DMD, MG, CIDP and Charcot-Marie-Tooth (CMT), among other conditions. Being an intricate part of developing innovative therapies for rare neuromuscular conditions is one of her biggest passions, along with her strong bonds with all her patients and their families. This unique relationship with her patients drives her to continue searching for therapeutic options for them. In addition to managing a busy patient load and conducting research, Dr. Castro has had many peer-reviewed publications and book chapters and has given multiple national and international lectures in English and Spanish. She also sits on several national medical advisory boards and steering committees. After more than ten years, Dr. Castro left academia to create a non-profit private practice and research institute for neuromuscular conditions. The research institute opened in November 2022, and the non-profit neuromuscular practice in January 2023. We are currently enrolling more than 10 research studies and have several protocols in the pipeline. We offer care to all neuromuscular patients, regardless of their insurance situation.
|
First Name
|
Last Name
|
Company
|
Email Address
|
Time Zone
|
|
|
|